Stock Code: 002728 Stock Abbreviation: Special Pharmaceutical Announcement Number: 2021-062
Bond code: 128025 Bond abbreviation: special one-to-one bond
The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and that there are no misrepresentations, misleading statements or material omissions.
Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently obtained the "Notice of Approval of Drug Supplement Application" of "Compound Sulfamethoxazole Tablets" approved by the State Drug Administration, and after review, the above drugs passed the consistency evaluation of generic drug quality and efficacy. The drug-related situations that passed the consistency evaluation this time are as follows:
1. The main content of the notice
2. Drug-related information
Compound sulfamethoxazole tablets are sulfonamide antibacterial drugs, which are a combination of sulfamethoxazole (SMZ) and trimethoprim (TMP), which is mainly used to prevent or treat infections caused by sensitive strains.
Compound sulfamethoxazole tablets are National Essential Drugs, Class A drugs of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2020).
Third, the impact on the company
The passing of the consistency evaluation of the quality and efficacy of the generic drug "compound sulfamethoxazole tablets" is the embodiment of the company's comprehensive strength in research and development capabilities, production and quality management system, and is also the recognition of the above comprehensive capabilities and product quality by the national drug regulatory authorities; at the same time, it also provides an important experience reference for the company's subsequent varieties to pass the consistency evaluation of the quality and efficacy of generic drugs. The "compound sulfamethoxazole tablets" has a positive impact on the company through the consistency evaluation of the quality and efficacy of generic drugs, which is conducive to the company's participation in the bidding of collection, increasing the sales channels of the product, and expanding the market share of the product.
4. Risk warning
Since the sales of drugs are affected by national policies, market environment and other uncertainties, the future production and sales of the drug is uncertain, please be cautious in making decisions and pay attention to preventing investment risks.
This is hereby announced.
Special One Pharmaceutical Group Co., Ltd
board of directors
October 22, 2021